



## Saad A. Khan, MD

Associate Professor of Medicine (Oncology)

Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Head and Neck Cancer Program**

900 Blake Wilbur Dr

3rd Fl MC 6560

Palo Alto, CA 94304

**Tel** (650) 498-6000      **Fax** (650) 724-1445

### Bio

---

#### BIO

Dr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.

Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.

Dr. Khan's research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.

He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.

Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym "NRG") to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.

Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.

He also is a member of the National Cancer Institute's Central IRB for Early Phase Clinical Trials.

When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach.

## CLINICAL FOCUS

- Medical Oncology

## ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Oncology
- Member, Stanford Cancer Institute

## PROFESSIONAL EDUCATION

- Board Certification, American Board of Internal Medicine , Hematology
- Board Certification, American Board of Internal Medicine , Medical Oncology
- Fellowship, Temple University Cancer Center , Hematology and Oncology
- Post-Doctoral Fellowship, Temple University , Fox Chase Cancer Center
- Residency, University of Massachusetts , Internal Medicine
- Medical Degree, Punjab Medical College , Faisalabad, Pakistan

## Research & Scholarship

---

### CLINICAL TRIALS

- A Study of EP0031 in Patients With Advanced RET-altered Malignancies, Recruiting
- Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer, Recruiting
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma, Not Recruiting
- A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors, Not Recruiting
- Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer, Not Recruiting
- An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery, Not Recruiting
- Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer, Not Recruiting
- Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer, Not Recruiting
- Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer, Not Recruiting
- SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies, Not Recruiting
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin, Not Recruiting
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers, Not Recruiting
- Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer, Not Recruiting
- 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC, Not Specified

## Publications

### PUBLICATIONS

- **Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer.** *JCI insight*  
Fernandez, K. A., Chowdhury, A. S., Bonczkowski, A., Allen, P. D., Campbell, M. H., Lee, D. S., Malhotra, C., Page, B. R., Mulford, D. A., Ortiz, C. E., Santa Maria, P. L., Kullar, P., Khan, et al  
2025; 10 (20)
- **Neoadjuvant chemotherapy and surgery versus surgery for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) ECOG-ACRIN EA3163.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Saba, N. F., Flamand, Y., Lin, D. T., Chung, C. H., McDonald, M. W., Flampouri, S., Khan, S. A., Snyderman, C. H., Hanna, E. Y., El-Sayed, I. H., Solares, C. A., Le, C. H., Ghaly, et al  
2025
- **Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.** *Head & neck*  
Bhatia, A., Mehra, R., Bauman, J., Khan, S. A., Wei, W., Neumeister, V., Sandoval-Schaefer, T., Alpaugh, R. K., Lango, M., Rimm, D. L., Ridge, J. A., Burtness, B.  
2025
- **First-in-Human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Colevas, A. D., Talebi, Z., Winters, E., Even, C., Lee, V. H., Gillison, M. L., Khan, S. A., Lu, R., Pinsky, B. A., Soldan, S. S., Vladmirova, O., Lieberman, P. M., Messick, et al  
2025
- **Case report: Dramatic impact of DNA next generation sequencing results using specific targeted therapies-ALK and PIK3CA.** *Frontiers in oncology*  
Cullum, S., Vang, H., Glover, M., Alammarah, H., Morton, H., Pham, N., Rahman, M., Khan, S. A.  
2024; 14: 1462930
- **Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.** *The Journal of experimental medicine*  
Tsimberidou, A. M., Alayli, F. A., Okrah, K., Drakaki, A., Khalil, D. N., Kummar, S., Khan, S. A., Hodi, F. S., Oh, D. Y., Cabanski, C. R., Gautam, S., Meier, S. L., Amouzgar, et al  
2024; 221 (10)
- **Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.** *Current treatment options in oncology*  
Abdalla, A. S., Rahman, M., Khan, S. A.  
2024
- **Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.**  
Colevas, A., Rudek, M. A., Even, C., Lee, V., Gillison, M. L., Khan, S. A., Lu, R., Winters, E., Biedermann, S., Lai, S., Messick, T.  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Opioid prescribing patterns for head and neck cancer radiation patients, with a comparison to breast cancer radiation patients.**  
Lasonde, B., Lu, R., Hawa, S., Biedermann, S., Lai, S., Winters, E., Khan, S. A.  
LIPPINCOTT WILLIAMS & WILKINS.2023: e18051
- **Opioid prescribing patterns for head and neck cancer radiation patients, with a comparison to breast cancer radiation patients**  
Lasonde, B., Lu, R., Hawa, S., Biedermann, S., Lai, S., Winters, E., Khan, S. A.  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.** *The Lancet. Oncology*  
Sherman, E. J., Harris, J., Bible, K. C., Xia, P., Ghossein, R. A., Chung, C. H., Riaz, N., Gunn, G. B., Foote, R. L., Yom, S. S., Wong, S. J., Koyfman, S. A., Dzeda, et al  
2023

- **AMADEUS TRIAL: TUMOR AGNOSTIC PRE- AND ONTREATMENT BIOMARKERS OF RESPONSE TO NIVOLUMAB PLUS IPILIMUMAB CORRELATE WITH ONTREATMENT TUMORAL T CELL INFILTRATION**  
Alayli, F., Okrah, K., Tsimberidou, A., Drakaki, A., Khalil, D., Khan, S., Hodi, S., Oh, D., Amouzgar, M., Guatam, S., Kageyama, R., Pfeiffer, S., Meier, et al  
BMJ PUBLISHING GROUP.2022: A614
- **Abemaciclib in metastatic or locally advanced anaplastic thyroid cancer.**  
Khanna, V., Miles, C., Sundaram, V., Sheth, S., Steffen, M., Biedermann, S., Jun, D., Winters, E., Khan, S. A.  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. *Investigational new drugs***  
McLean, L. S., Morris, T. A., Gramza, A., Liu, S., Khan, S. A., Colevas, A. D., Pearce, T., Rischin, D.  
2022
- **Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma. *PET clinics***  
Abdalla, A. S., Sheybani, N. D., Khan, S. A.  
2022
- **Risk factors for ED visits and admissions during outpatient chemotherapy in head and neck cancer**  
Shukla, N., Saraswathula, A., Khan, S. A., Divi, V.  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Extracapsular extension, pathologic node status, and adjuvant treatment in primary surgery patients with human papillomavirus-mediated oropharyngeal cancer: A national hospital-based retrospective cohort analysis. *Head & neck***  
Day, A. T., Yang, A. M., Tanamal, P., Blackwell, J., Wang, E., Sumer, B. D., Bishop, J. A., Hughes, R. S., Khan, S. A., Sher, D. J.  
2021
- **NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.**  
Lai, S., Torres-Saavedra, P. A., Dunlap, N. E., Beadle, B., Chang, S. S., Subramaniam, R. M., Yu, J., Lowe, V. J., Khan, S. A., Truong, M., Bell, D., Liu, C. Z., Kovalchuk, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers. *Surgical pathology clinics***  
Palsgrove, D., Allahabadi, S., Khan, S. A.  
2021; 14 (1): 151–63
- **Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)**  
Khan, S., Sun, Z., Pillai, R., Dahlberg, S., Malhotra, J., Keresztes, R., Ikpeazu, C., Ma, P., Ramalingam, S.  
ELSEVIER SCIENCE INC.2021: S131-S132
- **Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors *JOURNAL FOR IMMUNOTHERAPY OF CANCER***  
Ahmed, M., von Itzstein, M. S., Sheffield, T., Khan, S., Fattah, F., Park, J. Y., Papat, V., Saltarski, J. M., Gloria-McCutchen, Y., Hsiehchen, D., Ostmeyer, J., Khan, S. A., Sultana, et al  
2021; 9 (6)
- **Survivin expression and impact on head and neck cancer outcomes. *Oral oncology***  
Khan, S. A., Burke, M., Zhu, F., Yang, D., Dubyk, C., Mehra, R., Lango, M. J., Ridge, J. A., Sher, D. J., Burtness, B.  
2020; 112: 105049
- **Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks *ORAL ONCOLOGY***  
Day, A. T., Sher, D. J., Lee, R. C., Truelson, J. M., Myers, L. L., Sumer, B. D., Stankova, L., Tillman, B. N., Hughes, R. S., Khan, S. A., Gordin, E. A.  
2020; 105: 104684
- **Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon *ONCOLOGIST***

- Khan, S., von Itzstein, M. S., Lu, R., Bermas, B. L., Karp, D. R., Khan, S. A., Fattah, F. J., Park, J. Y., Saltarski, J. M., Gloria-McCutchen, Y., Xie, Y., Li, Q., Wakeland, et al  
2020; 25 (5): E753-E757
- **Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer** *ONCOLOGY*  
Sacks, R., Law, J. Y., Zhu, H., Beg, M. S., Gerber, D. E., Sumer, B. D., Myers, L. L., Truelson, J. M., Nedzi, L., Sher, D., Hughes, R. S., Khan, S. A.  
2020; 98 (3): 179-185
  - **Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.** *The oncologist*  
Bendell, J. n., Sharma, S. n., Patel, M. R., Windsor, K. S., Wainberg, Z. A., Gordon, M. n., Chaves, J. n., Berlin, J. n., Brachmann, C. B., Zavadovskaya, M. n., Liu, J. n., Thai, D. n., Bhargava, et al  
2020
  - **Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors**  
Melear, J., Lakhani, N., O'Shaughnessy, J. A., Wilks, S. T., Khan, S., Chandana, S. R., Tolcher, A. W., Papadopoulos, K. P., Cole, Y., Rivas, K., Ghosh, R., Sinclair, S., Lutz, et al  
AMER ASSOC CANCER RESEARCH.2019
  - **Therapy with tyrosine kinase inhibitor lenvatinib in radioactive iodine-naive advanced differentiated thyroid cancer** *INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY*  
Sukumar, J., Moore, W., Khan, S. A.  
2019; 6 (4)
  - **Head and neck neuroendocrine tumors at a single institution over 15 years** *CLINICAL CASE REPORTS*  
Bacalao, M., Beg, M. S., Cavuoti, D., Zhu, H., Sumer, B., Myers, L., Truelson, J., Nedzi, L., Sher, D., Hughes, R., Khan, S. A.  
2019; 7 (12): 2508-2512
  - **Association of electronic medical record (EMR) QTc alerts with higher mortality within 10 days for patients with blood, lung, GI, and soft tissue cancer.**  
Bleiberg, B., Xie, D., Lightfoot, T., Reisch, J., Khan, S. A.  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Confluent tracheal recurrences of head and neck squamous cell carcinoma** *CLINICAL CASE REPORTS*  
Bleiberg, B., Abu-Hijleh, M., Moore, W., Khan, S. A.  
2019; 7 (10): 1849-1853
  - **Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*  
Khan, S. A., Ci, B., Xie, Y., Gerber, D. E., Beg, M. S., Sherman, S. I., Cabanillas, M. E., Busaidy, N. L., Burtness, B. A., Heilmann, A. M., Bailey, M., Ross, J. S., Sher, et al  
2019; 41 (6): 1928-1934
  - **Evaluating sociodemographic, behavioral and psychologic disparities in 918 head and neck cancer survivors.**  
Day, A. T., Vasudevan, A., Wynings, E., Balachandra, S., Khan, S. A., Sumer, B. D., Murphy, C. C.  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Risk of Unplanned Hospital Encounters in Patients Treated With Radiotherapy for Head and Neck Squamous Cell Carcinoma** *JOURNAL OF PAIN AND SYMPTOM MANAGEMENT*  
Moore, Z. R., Nhat-Long Pham, Shah, J., Nedzi, L., Sumer, B. D., Day, A. T., Khan, S. A., Sher, D. J.  
2019; 57 (4): 738-+
  - **Association between treatment delays and oncologic outcome in patients treated with surgery and radiotherapy for head and neck cancer** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*  
Tumati, V., Hoang, L., Sumer, B. D., Truelson, J. M., Myers, L. L., Khan, S., Hughes, R. S., Nedzi, L., Sher, D. J.  
2019; 41 (2): 315-321
  - **Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients** *CLINICAL CANCER RESEARCH*  
Kobayashi, M., Chung, J., Beg, M., Arriaga, Y., Verma, U., Courtney, K., Mansour, J., Haley, B., Khan, S., Horiuchi, Y., Romani, V., Harker, D., Gopal, et al

2019; 25 (2): 828-838

- **Immune dysregulation in cancer patients developing immune-related adverse events** *BRITISH JOURNAL OF CANCER*  
Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J., Gloria-McCutchen, Y., Lu, R., Xie, Y., Li, Q., Wakeland, E., Gerber, D. E.  
2019; 120 (1): 63-68
- **Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*  
Singh, J., Moore, W., Fattah, F., Jiang, X., Zheng, J., Kurian, P., Beg, M. S., Khan, S. A.  
2019; 41 (1): E11-E15
- **Comparative effectiveness of primary radiotherapy versus surgery in elderly patients with locally advanced oropharyngeal squamous cell carcinoma** *ORAL ONCOLOGY*  
Sher, D. J., Yan, J., Day, A., Sumer, B. D., Nhat-Long Pham, Khan, S., Zhu, H.  
2019; 88: 18-26
- **Prevalence and usage patterns of opiates in patients with lung, breast, and head and neck cancer.**  
Westbrook, K., Ahn, C., Khan, S. A.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Pan-squamous genomic profiling stratified by anatomic tumor site and viral association**  
Montesion, M., Chung, C. H., Sokol, E. S., Khan, S. A., Kang, H., Albacker, L. A., Johnson, J. M., Frampton, G. M., Miller, V. A., Ross, J. S., Ali, S. M.  
OXFORD UNIV PRESS.2018
- **Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*  
Beg, M. S., Gupta, A., Sher, D., Ali, S., Khan, S., Gao, A., Stewart, T., Ahn, C., Berry, J., Mortensen, E. M.  
2018; 41 (8): 766-771
- **Comprehensive genomic profiling of anaplastic thyroid carcinoma**  
Bowles, D. W., Ross, J. S., Gay, L. M., Agrawal, V., Ali, S., Khan, S. A.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy**  
Khan, S. A., Kurian, P., Mobley, B., Burks, T., Beg, M., Ross, J. S., Ali, S., Bowles, D. W.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Underlying host immune dysregulation in cancer patients developing immune-related adverse events.**  
Gerber, D. E., Khan, S., Luo, X., Khan, S. A., Fattah, F., Saltarski, J., Gloria-McCutchen, Y., Park, J., Xie, Y., Li, Q., Wakeland, E.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy** *ONCOIMMUNOLOGY*  
Mohamad, O., de Leon, A., Schroeder, S., Leiker, A., Christie, A., Zhang-Velten, E., Trivedi, L., Khan, S., Desai, N. B., Laine, A., Albuquerque, K., Iyengar, P., Arriaga, et al  
2018; 7 (7): e1440168
- **How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis** *LUNG CANCER*  
Khan, S. A., Pruitt, S. L., Xuan, L., Makris, U., Gerber, D. E.  
2018; 115: 97-102
- **Risk of contralateral nodal failure following ipsilateral IMRT for node-positive tonsillar cancer** *ORAL ONCOLOGY*  
Gottumukkala, S., Nhat-Long Pham, Sumer, B., Myers, L., Truelson, J., Nedzi, L., Khan, S., Hughes, R., Sher, D. J.  
2017; 75: 35-38
- **Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients**  
Li, J., Harper, J., Bhulani, N., Gerber, D. E., Khan, S. A., Madrigales, A., Gates, S., Touns, M., Beg, M.  
AMER SOC CLINICAL ONCOLOGY.2017
- **Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

- Arora, N., Gupta, A., Zhu, H., Christie, A., Meyer, J. J., Khan, S. A., Beg, M. S.  
2017; 15 (8): 998-1004
- **Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer** *AMERICAN JOURNAL OF ROENTGENOLOGY*  
Goel, R., Moore, W., Sumer, B., Khan, S., Sher, D., Subramaniam, R. M.  
2017; 209 (2): 289-303
  - **Blocking the DC-HIL receptor reverses the T-cell suppression induced by proliferating myeloid-derived suppressor cells in common cancer types**  
Kobayashi, M., Chung, J., Beg, M., Arriaga, Y., Verma, U., Courtney, K., Mansour, J., Haley, B., Khan, S., Horiuchi, Y., Harker, D., Gopal, P., Cruz, et al  
AMER ASSOC CANCER RESEARCH.2017
  - **Genomic profiling of squamous malignancies across anatomic sites.**  
Chung, C. H., Frampton, G., Chalmers, Z., Chung, J., Khan, S. A., Schrock, A., Gay, L. M., Sharma, N., Elvin, J., Fabrizio, D., Connelly, C. F., Kang, H., Stephens, et al  
AMER SOC CLINICAL ONCOLOGY.2017
  - **Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).**  
Tawfik, B., Gerber, D. E., Burtness, B., Hughes, R. S., Myers, L. L., Sumer, B. D., Truelson, J., Strom, T., Kurian, P., Saleem, S., Pearson, J., Zhu, H., Khan, et al  
AMER SOC CLINICAL ONCOLOGY.2017
  - **In-human activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer.**  
Singh, J., Fattah, F., Burks, T., Zheng, J., Jiang, X., Kurian, P., Saleem, S., Pearson, J., Khan, S. A.  
AMER SOC CLINICAL ONCOLOGY.2017
  - **Comparative effectiveness of primary radiotherapy versus surgery in oropharyngeal squamous cell carcinoma in elderly patients: A SEER-Medicare analysis.**  
Sher, D., Yan, J., Strom, T., Khan, S. A., Zhu, H.  
AMER SOC CLINICAL ONCOLOGY.2017
  - **Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.**  
Khan, S. A., Puligandla, M., Dahlberg, S., Masters, G. A., Langer, C. J., Brahmer, J. R., Hanna, N. H., Bonomi, P., Gerber, D. E., Johnson, D. H., Schiller, J. H., Ramalingam, S. S.  
AMER SOC CLINICAL ONCOLOGY.2017
  - **Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*  
Brown, T. J., Sher, D. J., Nedzi, L. A., Hughes, R. S., Beg, M. S., Mull, J., Sarode, V. R., Khan, S. A.  
2017; 39 (5): E69-E71
  - **Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions** *ONCOLOGIST*  
Vanden Borre, P., Schrock, A. B., Anderson, P. M., Morris, J. C., Heilmann, A. M., Holmes, O., Wang, K., Johnson, A., Waguespack, S. G., Ou, S., Khan, S., Fung, K., Stephens, et al  
2017; 22 (3): 255-263
  - **Racial and gender disparities in therapy and outcomes of squamous cell cancer of the anus**  
Gupta, A., Arora, N., Zhu, H., Christie, A., Meyer, J., Khan, S. A., Beg, M. S.  
AMER SOC CLINICAL ONCOLOGY.2017
  - **National Patterns of Care and Predictors of Neoadjuvant and Concurrent Chemotherapy Use With Definitive Radiotherapy in the Treatment of Patients With Oropharyngeal Squamous Cell Carcinoma** *CANCER*  
Sher, D. J., Rusthoven, C. G., Khan, S. A., Fidler, M., Zhu, H., Koshy, M.  
2017; 123 (2): 273-282
  - **A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck** *CANCER INVESTIGATION*  
Chun, S. G., Hughes, R., Sumer, B. D., Myers, L. L., Truelson, J. M., Khan, S. A., Ma, T., Xie, Y., Yordy, J. S., Cooley, S., Wu, J., Choy, H., Nedzi, et al

2017; 35 (1): 23-31

- **Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options** *JAMA ONCOLOGY*  
Khan, S. A., Pruitt, S. L., Xuan, L., Gerber, D. E.  
2016; 2 (11): 1507-1508
- **Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit** *INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY*  
Cabanillas, M. E., Busaidy, N. L., Khan, S. A., Gunn, G., Dadu, R., Rao, S. N., Waguespack, S. G.  
2016; 3 (3): 221-233
- **Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era** *JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY*  
Sher, D. J., Nedzi, L., Khan, S., Hughes, R., Sumer, B. D., Myers, L. L., Truelson, J. M., Koshy, M.  
2016; 142 (8): 777-788
- **A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).**  
Rischin, D., Boyer, M. J., Brzezniak, C. E., Colevas, A., Doebele, R., Gilbert, J., Gitlitz, B., Khan, S. A., Mehra, R., Seiwert, T. Y., Kroll, S., Pearce, T. E., Liu, et al  
AMER SOC CLINICAL ONCOLOGY.2016
- **Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).**  
Khan, S. A., Ci, B., Gerber, D. E., McFadden, D. G., Beg, M., Xie, Y., Kurian, P., Cabanillas, M. E., Busaidy, N., Sherman, S. I., Heilmann, A., Ross, J. S., Bailey, et al  
AMER SOC CLINICAL ONCOLOGY.2016
- **Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.**  
Bhatia, A. K., Mehra, R., Khan, S. A., Egleston, B. L., Alpaugh, R., Lango, M., Ridge, J. A., Burtness, B.  
AMER SOC CLINICAL ONCOLOGY.2016
- **Prevalence of autoimmune conditions among patients with lung cancer: Implications for immunotherapy treatment options.**  
Khan, S. A., Xuan, L., Pruitt, S., Gerber, D. E.  
AMER SOC CLINICAL ONCOLOGY.2016
- **Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers** *JAMA ONCOLOGY*  
Jean, G. W., Mani, R. M., Jaffry, A., Khan, S. A.  
2016; 2 (4): 529-534
- **Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis** *ORAL ONCOLOGY*  
Sher, D. J., Schwartz, D. L., Nedzi, L., Khan, S., Hughes, R., Fidler, M., Koshy, M.  
2016; 54: 58-67
- **Racial and sex disparities in changing trends of squamous cell cancer of the anus (SSCA).**  
Gupta, A., Zhu, H., Christie, A., Meyer, J., Khan, S. A., Beg, M.  
AMER SOC CLINICAL ONCOLOGY.2016
- **ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.** *ESMO open*  
Dittrich, C. n., Kosty, M. n., Jezdic, S. n., Pyle, D. n., Berardi, R. n., Bergh, J. n., El-Saghir, N. n., Lotz, J. P., Österlund, P. n., Pavlidis, N. n., Purkalne, G. n., Awada, A. n., Banerjee, et al  
2016; 1 (5): e000097
- **Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma**  
Heilmann, A., Subbiah, V., Wang, K., Elvin, J., Chmielecki, J., Yelensky, R., Vergilio, J. A., Erlich, R., Lipson, D., Ross, J., Miller, V., Ali, S., Stephens, et al  
ELSEVIER SCI LTD.2015: S562
- **A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)** *LUNG CANCER*

Owonikoko, T. K., Dahlberg, S. E., Khan, S. A., Gerber, D. E., Dowell, J., Moss, R. A., Belani, C. P., Hann, C. L., Aggarwal, C., Ramalingam, S. S. 2015; 89 (1): 66-70

- **Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities.**

Khan, S. A., Bauman, J. E., Burtness, B., Frankel, A. E., Harper, J., Hughes, R. S., Kurian, P., Myers, L. L., Nedzi, L., Schwartz, D. L., Sumer, B. D., Truelson, J., Zhu, et al  
AMER SOC CLINICAL ONCOLOGY.2015

- **Neuroendocrine tumors of the head and neck: SEER analysis of survival and incidence.**

Khan, S. A., Zhu, H., Bacalao, M.  
AMER SOC CLINICAL ONCOLOGY.2015

- **Use of 18-FDG PET in Determination of Disease Extent in HPV/p16-Positive Oropharyngeal Squamous Cell Carcinoma**

Gannavarapu, B., Sumer, B. D., Prabhu, R. S., Yordy, J. S., Nedzi, L. A., Khan, S. A., Schwartz, D., Chen, S. A.  
ELSEVIER SCIENCE INC.2014: S519-S520

- **Patterns of distant metastases in HPV-positive head and neck squamous cell carcinoma.**

Law, J., Chen, S., Gerber, D. E., Hughes, R. S., Madrigales, A., Myers, L. L., Nedzi, L., Sumer, B. D., Truelson, J., Yordy, J., Zhu, H., Khan, S. A.  
LIPPINCOTT WILLIAMS & WILKINS.2014